AstraZeneca's first-in-class severe asthma therapy Tezspire has been approved in the EU in a new pen injector formulation ... R&D Mene Pangalos said the new device would help support the use ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Dupixent (dupilumab) is a brand-name injection that’s prescribed for treating asthma. This article covers topics such as side effects, dosage, and how Dupixent works. Dupixent is available as a ...

SYDNEY, Feb 4 (Reuters) - Australia has banned DeepSeek from all government devices over concerns that the Chinese artificial intelligence startup poses security risks, the government said on Tuesday.

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...

Apple's slate of 2025 products look to be dominated by a large number of low-cost and entry-level devices. Here's what to expect. With advancements like Apple Intelligence and all-new in-house ...

No longer is the stylus only useful to creatives and scribes, either. The pen makes interacting with your device a more organic experience, whether you jot down notes, revel in remote photography ...

Just before TikTok’s temporary ban, Charli D’Amelio surprised fans with a confession about the 2020 ‘anxiety pen’ controversy.

Furthermore, the successful launch of Dupixent for chronic obstructive pulmonary disease (COPD) has garnered significant coverage from top commercial and Medicare payers, indicating strong market ...